FT.com / Search

1-10 of 465,554 results for In re: Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation

Sorry, we found no matches with all of your words. Here are the nearest matches with some of the words.

FT Suggests - Try these pages on FT.com

Sort by:

Relevance
Date

January 31, 2006
Lawsuits divide US drugs groups
...reached $1bn, after adding $295m in the fourth quarter. Meanwhile...entering the tail end of nine years of litigation over withdrawn fen-phen diet drugs. Despite rising legal costs...of Columbia. Merck withdrew Vioxx in September 2004 after finding it increased...will save it billions of dollars in liability costs seen with early big litigation settlements such as Wyeth’s almost...is also looking for an answer to re-ignite sales and profit growth...fourth-largest biotech company. Key products such as Enbrel, a protein to treat... By Christopher Bowe in New York
April 15, 2005
From pipe dream to pipeline
...A reminder closer to home comes in the form of the water tower that spoils...more successful than his predecessor in lobbying the authorities to get it...If some of Wyeth's most recent products win regulatory approval, and the...more time to devote to the issue. DRUGS AND DRAMA: LEARNING THE LESSONS OF PRODUCT LIABILITY LAWSUITS As growing concerns about...drug Pondimin, part of a combination diet therapy called fen-phen, was used...people but withdrawn from the market in 1997 after concerns over health problems...concerns around fen-phen and, during litigation, allegations emerged of internal... By Andrew Jack
January 31, 2005
Wyeth sets aside a further $4.5bn
...important new products. The experimental drugs, including a new antibiotic and new...Martin, Wyeth chief financial officer. In addition, two of Wyeth's biggest products face stern competition this year...year. Wyeth's $4.5bn addition to litigation reserves - over its diet drugs Pondimin and Redux used in a so called fen-phen combination... By Christopher Bowe in New York
February 5, 2010
Wall St volatile after mixed US jobs report
...department also reported a surprise decline in January payrolls.Futures initially turned...have come to accept the idea that we’re in recovery, their expectations have risen...surging 40 per cent to $60.96. Air Products and Chemicals, Airgas’s rival, launched...industrial gas group.Meanwhile, shares in Air Products fell 6.9 per cent to $68.64.Aetna... By Samantha Pearson in New York
December 29, 2009
Drugmaker has unique model to compete
...with smaller European and American drugs groups which also lack sales forces...sales force. “Let’s say you’re number five in the region and you want to catch up with...the number of people promoting your products?” Even when Hikma is selling generic drugs that have come off-patent it still...producing branded versions of generic drugs, and markets its products as of superior quality to other available...This is where the sales reps come in handy. “We don’t compete on price...cents. But our message is that we’re giving you the same quality as the... By John O’Doherty
December 30, 2009
Drugmaker has unique model to compete with rivals
...the Middle East. Until now Hikma's in-licensing deals have focused on these...combined with smaller European and American drugs groups that also lack sales forces...this sales force. "Let's say you're number five in the region and you want to catch up with...twice the number of people promoting your products?" Even when Hikma is selling generic drugs that have come off-patent, it still... By John O'Doherty
January 28, 2010
Goldman plays key role in Greece rescue
...also useful in Goldman’s strong role in Greece is also imporant to its lucrative business...clients who have at least €100m to invest in riskier products than ships and real estate.“They’re not looking to handle lots of small clients...that Goldman mooted the sale of equity in NBG to Bank of China, the country’s third... By Kerin Hope in Athens and Megan Murphy in London
February 8, 2010
Alliance to buy Cambridge Laboratories
...good match, and it gives us quite a boost in scale. It’s the biggest acquisition we’ve done yet. It’s our 18th in 12 years.”Alliance will pay a fixed...between £1.6m and £2.1m if one of the drugs has its licence period extended...result of the acquisition.Among the products that Alliance will be acquiring are...acquired everything which Cambridge had in the UK and Ireland, connected with the trading...with their development business we’re not touching.”Shares in Alliance Pharma... By John O’Doherty
January 12, 2010
Tom Bolt of Lloyd’s of London
...in timing, when would it happen. PD In much longer term the concern obviously...lot of insurers buying and investing in these products themselves and just passing around the...the jurisdiction and whether you’re holding more or less capital. So I...attractive write to take the similar risk in through the insurance security rap rather...in response to capacity shortages for liability policies among other things. And... By Paul J Davies
January 4, 2010
Diagnostics sector buoyed by point-of-care innovations
...expanded beyond this simple test to develop products in one of the fastest-growing fields of...everything from disease to genetics to diet is undergoing a transformation, as cumbersome...spot tests that can be administered in GP surgeries or in a patient's home...testing infectious diseases. "If you're in Africa, and test somebody for HIV at... By John O'Doherty